| External factors: | Methoxyeugenol |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Endometrial cancer |
| Experiment: | Western blot//Flow cytometry |
| Description: | According to the median fluorescence intensity(MFI), methoxyeugenol-treated cells did not show an increase in the enzymatic activity of β-galactosidase. As expected, the positive control H2O2 (500 μM) confirmed the SA-β-gal induction. Representative flow cytometric plots are shown. |
| Regulatory pathway: | p53-p21 |
| R-EF-Pathway: | Activation |
| Official symbol(s): | TP53-CDKN1A |
| Pathway experiment: | PCR |
| Pathway description: | p53 expression increase in response to treatments with MET and CPPD. There was no difference in the expression levels of p16 in response to the treatment. MET treatment (60 μM) also raised the expression389 levels of p21 and yet decreased the expression levels of CDK4. and CDK6. |
Annotation: